Emmajay Sutherland

Emmajay Sutherland

Auto-generated profile, based on publicly available information

Emmajay Sutherland

University of Washington

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2021 in Faraday Discussions
Verified
Journal Article
Closed access
PDF file
JCJosé Casaban
José Casaban
YZYuancheng Zhang
Yuancheng Zhang
RPRaul Pacheco
Raul Pacheco
CCCiaran Coney
Ciaran Coney
CHCatherine Holmes
Catherine Holmes
AMAshleigh Moore
Ashleigh Moore
We demonstrate the one-step mechanochemical production of MOF shaped bodies at large scale with bespoke geometry, strength and stability.

15 October 2025 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
KKKathryn Kothlow
Kathryn Kothlow
HSHaley M. Schramm
Haley M. Schramm
KMKayla A. Markuson
Kayla A. Markuson
JRJacob H. Russell
Jacob H. Russell
ESEmmajay Sutherland
Emmajay Sutherland
NRNicholas M. Riley
Nicholas M. Riley
Glycopeptide tandem mass spectra typically contain numerous glycan-specific fragments that can inform several features of glycan modifications, including glycan class, composition, and structure. While these fragment ions are often straightforward to observe by eye, few tools exist to systemically explore these common glycopeptide spectral features or explore their relationships with each other. Instead, most studies rely on manual inspection to understand glycan-informative ion content in their data, or they are restricted to evaluating the presence of these ions only in the small fraction of spectra that are identified by glycopeptide search algorithms. Here we introduce GlyCounter as a freely available, open-source tool to rapidly extract oxonium, Y-type, and custom ion information from raw data files. We highlight GlyCounter's utility by evaluating glycan-specific fragments in a diverse selection of publicly available datasets to demonstrate how others in the field can make immediate use of this software. In several cases, we show how conclusions drawn in these publications are evident simply through GlyCounter's extracted ion information without requiring database searches or experiment-specific programs. Although one of our goals is to decouple spectral evaluation from glycopeptide identification, we also show that evaluating oxonium ion content with GlyCounter can supplement a database search as valuable spectral evidence to validate conclusions. In all, we present GlyCounter as a user-friendly platform that can be easily incorporated into most glycoproteomic workflows to refine sample preparation, data acquisition, and post-acquisition identification methods through straightforward evaluation of the glycan content of glycoproteomic data. Software and instructions are available at https://github.com/riley-research/GlyCounter.

12 November 2024 in Journal of Proteome Research
Verified
Journal Article
Closed access
ESEmmajay Sutherland
Emmajay Sutherland
TVTim S. Veth
Tim S. Veth
WBWilliam D. Barshop
William D. Barshop
JRJacob H. Russell
Jacob H. Russell
KKKathryn Kothlow
Kathryn Kothlow
NRNicholas M. Riley
Nicholas M. Riley

25 August 2022 in Communications Chemistry
Verified
Journal Article
Open access
PDF file
ESEmmajay Sutherland
Emmajay Sutherland
CHChristopher John Harding
Christopher John Harding
CCClarissa Melo Czekster
Clarissa Melo Czekster
Cyclodipeptide synthases (CDPSs) generate a wide range of cyclic dipeptides using aminoacylated tRNAs as substrates. Histidine-containing cyclic dipeptides have important biological activities as anticancer and neuroprotective molecules. Out of the 120 experimentally validated CDPS members, only two are known to accept histidine as a substrate yielding cyclo(His-Phe) and cyclo(His-Pro) as products. It is not fully understood how CDPSs select their substrates, and we must rely on bioprospecting to find new enzymes and novel bioactive cyclic dipeptides. Here, we developed an in vitro system to generate an extensive library of molecules using canonical and non-canonical amino acids as substrates, expanding the chemical space of histidine-containing cyclic dipeptide analogues. To investigate substrate selection we determined the structure of a cyclo(His-Pro)-producing CDPS. Three consecutive generations harbouring single, double and triple residue substitutions elucidated the histidine selection mechanism. Moreover, substrate selection was redefined, yielding enzyme variants that became capable of utilising phenylalanine and leucine. Our work successfully engineered a CDPS to yield different products, paving the way to direct the promiscuity of these enzymes to produce molecules of our choosing.

15 January 2021 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
CHChristopher J. Harding
Christopher J. Harding
ESEmmajay Sutherland
Emmajay Sutherland
JHJane G. Hanna
Jane G. Hanna
DHDouglas Houston
Douglas Houston
CCClarissa M. Czekster
Clarissa M. Czekster
Cyclodipeptide synthases (CDPSs) produce a variety of cyclic dipeptide products by utilising two aminoacylated tRNA substrates. We sought to investigate the minimal requirements for substrate usage in this class of enzymes as the relationship between CDPSs and their substrates remains elusive. Here, we investigated the Bacillus thermoamylovorans enzyme, BtCDPS, which synthesises cyclo(L-Leu–L-Leu). We systematically tested where specificity arises and, in the process, uncovered small molecules (activated amino esters) that will suffice as substrates, although catalytically poor. We solved the structure of BtCDPS to 1.7 Å and combining crystallography, enzymatic assays and substrate docking experiments propose a model for how the minimal substrates interact with the enzyme. This work is the first report of a CDPS enzyme utilizing a molecule other than aa-tRNA as a substrate; providing insights into substrate requirements and setting the stage for the design of improved simpler substrates.

17 May 2022 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PSPamela Sweeney
Pamela Sweeney
AGAshleigh Galliford
Ashleigh Galliford
AKAbhishek Kumar
Abhishek Kumar
DRDINESH RAVINDRARAJU
DINESH RAVINDRARAJU
NKNaveen B. Krishna
Naveen B. Krishna
RSRafael G. da Silva
Rafael G. da Silva
The enzyme m1A22-tRNA methyltransferase (TrmK) catalyses the transfer of a methyl group to the N1 of adenine 22 in bacterial tRNAs. TrmK is essential for Staphylococcus aureus survival during infection, but has no homologue in mammals, making it a promising target for antibiotic development. Here we characterize the structure and function of S. aureus TrmK using X-ray crystallography, binding assays, and molecular dynamics simulations. We report crystal structures for the S. aureus TrmK apoenzyme as well as in complexes with methyl donor SAM and co-product product SAH. Isothermal titration calorimetry showed that SAM binds to the enzyme with favourable but modest enthalpic and entropic contributions, whereas SAH binding leads to an entropic penalty compensated for by a large favourable enthalpic contribution. Molecular dynamics simulations point to specific motions of the C-terminal domain being altered by SAM binding, which might have implications for tRNA recruitment. In addition, activity assays for S. aureus TrmK-catalysed methylation of A22 mutants of tRNALeu demonstrate that the adenine at position 22 is absolutely essential. In-silico screening of compounds suggested the multi-functional organic toxin plumbagin as a potential inhibitor of TrmK, which was confirmed by activity measurements. Furthermore, LC-MS data indicated the protein was covalently modified by one equivalent of the inhibitor, and proteolytic digestion coupled with LC-MS identified Cys92 in the vicinity of the SAM-binding site as the sole residue modified. These results identify a cryptic binding pocket of S. aureus TrmK, laying a foundation for future structure-based drug discovery.